Other studies, using the monoclonal antibody 8F1[43] have reported that the presence of ERCC1 protein is a prognostic marker of survival in early NSCLC and a predictor of outcome to adjuvant cisplatin-based chemotherapy; however, in a prior study in gastric cancer[44], it was unclear whether the poor clinical response of patients whose tumors had high pretreatment mRNA levels of ERCC1 resulted from tumor cell resistance to cisplatin-based chemotherapy or from a more aggressive tumor biology. This evidence concerns the gene ERCC1 and neoplasm.